SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) ...
Benchmark raised the firm’s price target on CapsoVision (CV) to $14 from $5 and keeps a Speculative Buy rating on the shares after the company announced that it submitted a 510(k) application to the ...
(RTTNews) - CapsoVision, Inc. (CV) on Thursday reported its financial results for the third quarter ended September 30, 2025. The company reported a net loss of $7.9 million or $0.17 per share, ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results